Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBIT (2016 - 2025)

Historic EBIT for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$14.3 million.

  • Northwest Biotherapeutics' EBIT rose 324.98% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.9 million, marking a year-over-year decrease of 278.38%. This contributed to the annual value of -$66.5 million for FY2024, which is 1981.7% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its EBIT stood at -$14.3 million for Q3 2025, which was up 324.98% from -$14.8 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' EBIT peaked at -$10.0 million during Q3 2021, and registered a low of -$21.1 million during Q2 2022.
  • For the 5-year period, Northwest Biotherapeutics' EBIT averaged around -$15.2 million, with its median value being -$14.8 million (2024).
  • Data for Northwest Biotherapeutics' EBIT shows a peak YoY increase of 7901.08% (in 2021) and a maximum YoY decrease of 14984.04% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' EBIT stood at -$10.7 million in 2021, then tumbled by 70.27% to -$18.2 million in 2022, then increased by 16.7% to -$15.1 million in 2023, then dropped by 22.17% to -$18.5 million in 2024, then increased by 22.59% to -$14.3 million in 2025.
  • Its EBIT was -$14.3 million in Q3 2025, compared to -$14.8 million in Q2 2025 and -$17.3 million in Q1 2025.